S&P 500   4,330.90 (+0.25%)
DOW   33,943.91 (-0.06%)
QQQ   358.81 (+0.25%)
AAPL   175.68 (+0.51%)
MSFT   316.54 (-0.15%)
META   299.23 (+0.05%)
GOOGL   130.57 (+0.25%)
AMZN   130.96 (+1.43%)
TSLA   245.05 (+0.07%)
NVDA   422.90 (+1.63%)
NIO   8.36 (-1.99%)
BABA   87.03 (-1.44%)
AMD   96.77 (+0.59%)
T   14.97 (-0.99%)
F   12.64 (+1.69%)
MU   69.12 (+0.35%)
CGC   0.94 (+11.93%)
GE   111.72 (+0.42%)
DIS   80.89 (-0.44%)
AMC   8.27 (+8.53%)
PFE   32.64 (-0.15%)
PYPL   58.45 (+0.98%)
NFLX   382.77 (+0.78%)
S&P 500   4,330.90 (+0.25%)
DOW   33,943.91 (-0.06%)
QQQ   358.81 (+0.25%)
AAPL   175.68 (+0.51%)
MSFT   316.54 (-0.15%)
META   299.23 (+0.05%)
GOOGL   130.57 (+0.25%)
AMZN   130.96 (+1.43%)
TSLA   245.05 (+0.07%)
NVDA   422.90 (+1.63%)
NIO   8.36 (-1.99%)
BABA   87.03 (-1.44%)
AMD   96.77 (+0.59%)
T   14.97 (-0.99%)
F   12.64 (+1.69%)
MU   69.12 (+0.35%)
CGC   0.94 (+11.93%)
GE   111.72 (+0.42%)
DIS   80.89 (-0.44%)
AMC   8.27 (+8.53%)
PFE   32.64 (-0.15%)
PYPL   58.45 (+0.98%)
NFLX   382.77 (+0.78%)
S&P 500   4,330.90 (+0.25%)
DOW   33,943.91 (-0.06%)
QQQ   358.81 (+0.25%)
AAPL   175.68 (+0.51%)
MSFT   316.54 (-0.15%)
META   299.23 (+0.05%)
GOOGL   130.57 (+0.25%)
AMZN   130.96 (+1.43%)
TSLA   245.05 (+0.07%)
NVDA   422.90 (+1.63%)
NIO   8.36 (-1.99%)
BABA   87.03 (-1.44%)
AMD   96.77 (+0.59%)
T   14.97 (-0.99%)
F   12.64 (+1.69%)
MU   69.12 (+0.35%)
CGC   0.94 (+11.93%)
GE   111.72 (+0.42%)
DIS   80.89 (-0.44%)
AMC   8.27 (+8.53%)
PFE   32.64 (-0.15%)
PYPL   58.45 (+0.98%)
NFLX   382.77 (+0.78%)
S&P 500   4,330.90 (+0.25%)
DOW   33,943.91 (-0.06%)
QQQ   358.81 (+0.25%)
AAPL   175.68 (+0.51%)
MSFT   316.54 (-0.15%)
META   299.23 (+0.05%)
GOOGL   130.57 (+0.25%)
AMZN   130.96 (+1.43%)
TSLA   245.05 (+0.07%)
NVDA   422.90 (+1.63%)
NIO   8.36 (-1.99%)
BABA   87.03 (-1.44%)
AMD   96.77 (+0.59%)
T   14.97 (-0.99%)
F   12.64 (+1.69%)
MU   69.12 (+0.35%)
CGC   0.94 (+11.93%)
GE   111.72 (+0.42%)
DIS   80.89 (-0.44%)
AMC   8.27 (+8.53%)
PFE   32.64 (-0.15%)
PYPL   58.45 (+0.98%)
NFLX   382.77 (+0.78%)
OTCMKTS:GNFTF

Genfit (GNFTF) Stock Forecast, Price & News

$3.80
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$3.80
$3.80
50-Day Range
$3.80
$3.80
52-Week Range
$3.13
$4.39
Volume
N/A
Average Volume
1,225 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GNFTF stock logo

About Genfit (OTCMKTS:GNFTF) Stock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GNFTF Price History

GNFTF Stock News Headlines

Kepler Capital Sticks to Their Buy Rating for Genfit (GNFTF)
SVB Securities Remains a Buy on Genfit SA (GNFT)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Genfit Gears Up For Primary Biliary Cholangitis Trial Data
Genfit (GNFTF) Receives a Buy from Kepler Capital
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
GENFIT Announces 2023 Financial Calendar
A Long Wait For Genfit May Be Worth It
Genfit S.A. (GNFT)
Analyzing Genfit's Short Interest
Hedge Funds Are Betting On Genfit SA (GNFT)
See More Headlines
Receive GNFTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GNFTF
CIK
N/A
Fax
N/A
Employees
148
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Jean-Francois Mouney (Age 68)
    Co-Founder & Chairman
    Comp: $395.2k
  • Mr. M. Pascal Prigent (Age 55)
    Chief Exec. Officer
    Comp: $598.95k
  • Prof. Bart Staels (Age 60)
    Co-Founder & Chairman of the Scientific Advisory Board
  • Mr. Thomas Baetz (Age 49)
    Chief Financial Officer
  • Mr. Pascal Caisey (Age 55)
    Chief Operating Officer
  • Dr. Meriam Kabbaj Ph.D. (Age 49)
    Chief Technology Officer
  • Dr. Dean W. Hum Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Jean-Christophe Marcoux (Age 45)
    Chief Corp. Affairs Officer, Head of Investor Relations & Head of ESG
  • Mr. Laurent Lannoo (Age 53)
    Corp. Sec. & Director of Legal Affairs
  • Ms. Stefanie Magner J.D. (Age 42)
    Chief Compliance Officer & Exec. VP of International Legal Affairs













GNFTF Stock - Frequently Asked Questions

How have GNFTF shares performed in 2023?

Genfit's stock was trading at $3.6901 at the beginning of the year. Since then, GNFTF stock has increased by 3.0% and is now trading at $3.80.
View the best growth stocks for 2023 here
.

Are investors shorting Genfit?

Genfit saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 18,500 shares, a drop of 16.7% from the August 15th total of 22,200 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.
View Genfit's Short Interest
.

What is Genfit's stock symbol?

Genfit trades on the OTCMKTS under the ticker symbol "GNFTF."

How do I buy shares of Genfit?

Shares of GNFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genfit's stock price today?

One share of GNFTF stock can currently be purchased for approximately $3.80.

How many employees does Genfit have?

The company employs 148 workers across the globe.

How can I contact Genfit?

Genfit's mailing address is Parc Eurasante, Loos, Hauts-de-France 59120. The official website for the company is www.genfit.com. The company can be reached via phone at (332) 016-4000.

This page (OTCMKTS:GNFTF) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -